Document Detail


Effects of short and long-term lithium treatment on serum prolactin levels in patients with bipolar affective disorder.
MedLine Citation:
PMID:  11294478     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
1. In this study, the authors sought to test the hypothesis that Li (lithium) treatment can induce alterations in PRL (prolactin) secretion in euthymic bipolar patients compared to controls and that short and long-term administration can lead to prolactin changes different from each other. 2. Twenty euthymic bipolar male patients on long-term lithium carbonate treatment for more than 6 months and 15 euthymic male bipolar patients on short-term Li treatment for shorter than 6 months who met DSM-IV criteria for bipolar affective disorder were included in the study. Seventeen age-matched healthy control males were chosen among the hospital staff. The mean +/- SD duration of Li use was 68.93+/-46.31 months in the long-term lithium-treated group and 4+/-3.42 months in the short-term lithium-treated group. 3. Serum PRL values in the long-term Li-treated group were significantly lower than those of the control group, while there was no significant difference in PRL values between the short-term Li-treated group and the control group. 4. Our study documents that short-term (<6 months) Li treatment does not induce any significant changes in PRL release in bipolar patients compared to normal control subjects while long-term Li treatment (>6 months) leads to lower PRL release compared to the controls. Furthermore, PRL has wide intra-interindividual and circadian variations Li-PRL relationship seems to be very complex and probably depends on various interactions among dopamine, serotonin and PRL. Therefore, further studies are needed to confirm the data.
Authors:
M Baştürk; F Karaaslan; E Esel; S Sofuoğlu; A Tutuş; I Yabanoğlu
Related Documents :
17164028 - What is a mood stabilizer?
3093468 - The comparative efficacy and safety of carbamazepine versus lithium: a randomized, doub...
31948 - Response to lithium carbonate.
23568228 - A randomized controlled trial examining the efficacy of motivational counseling with ob...
15611808 - The canadian optimal therapy of copd trial: design, organization and patient recruitment.
24287508 - Psychometric validation of the functional assessment of cancer therapy-brain (fact-br) ...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Progress in neuro-psychopharmacology & biological psychiatry     Volume:  25     ISSN:  0278-5846     ISO Abbreviation:  Prog. Neuropsychopharmacol. Biol. Psychiatry     Publication Date:  2001 Feb 
Date Detail:
Created Date:  2001-04-10     Completed Date:  2001-08-02     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8211617     Medline TA:  Prog Neuropsychopharmacol Biol Psychiatry     Country:  England    
Other Details:
Languages:  eng     Pagination:  315-22     Citation Subset:  IM    
Affiliation:
Department of Psychiatry, Erciyes University School of Medicine, Kayseri, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antimanic Agents / therapeutic use
Bipolar Disorder / blood,  drug therapy*
Erythrocytes / metabolism
Humans
Lithium / blood
Lithium Carbonate / therapeutic use*
Male
Prolactin / blood*,  secretion
Reference Values
Time Factors
Chemical
Reg. No./Substance:
0/Antimanic Agents; 554-13-2/Lithium Carbonate; 7439-93-2/Lithium; 9002-62-4/Prolactin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The visual backward masking deficit in schizophrenia.
Next Document:  The changes of biological markers and treatment efficacy in schizophrenia.